Sequoia Strategy Flags Elevance Health as Q4 Detractor; Revenue Rises 10%
Sequoia Strategy’s Q4 2025 letter revealed Elevance Health has been a detractor, with shares down 11.7% in the past month and 16.3% over twelve months. The insurer posted Q4 revenue of $49.3 billion, up 10% year-over-year, while maintaining a $72.3 billion market capitalization.
1. Hedge Fund Performance and Elevance Positioning
Sequoia Strategy posted a 9% return in Q4 2025 versus 2.7% for the S&P 500 and 21.9% for the year versus 17.9% for the index. The strategy focuses on high-quality, financially strong businesses and identified Elevance Health as one of its top five holdings, though it detracted from quarterly performance.
2. Elevance Health Share Performance
Shares have fallen 11.65% over the past month and 16.29% over the last twelve months through early February 2026, reflecting market volatility and managed care utilization concerns. This underperformance contrasted with sector peers and weighed on the fund’s relative returns.
3. Q4 2025 Financial Results
Elevance Health reported operating revenue of $49.3 billion in Q4, a 10% increase from Q4 2024, driven by growth in government-funded healthcare enrollment. The company held a market capitalization of $72.28 billion as of the most recent quarter.
4. Valuation and Strategic Outlook
The fund highlighted opportunistic entries into Elevance after Covid-induced utilization swings and noted prior valuations were on the high side of fair. It suggests that while fundamentals remain solid, certain AI stocks may offer superior upside potential and lower downside risk.